Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines

Veterinary Journal

Volumn 201, Issue 1, 2014, Pages 83-90

  Tomiyasu, Hirotaka ^a   Goto Koshino, Yuko ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

ABCB1; Akt; Canine; ERK; JNK; Lymphoma cell lines; Multidrug resistance; P glycoprotein

Indexed keywords

LUNG RESISTANCE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHODAMINE 123; S 1037; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; PHOSPHORYLCHOLINE; RIBONUCLEOPROTEIN;

ABCB1 GENE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B-CELL LEUKEMIA CELL LINE; B-CELL LYMPHOMA CELL LINE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DOG; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; IC 50; INTRACELLULAR SIGNALING; LRP GENE; LYMPHOMA CELL LINE; NONHUMAN; NUCLEOTIDE SEQUENCE; T-CELL LYMPHOMA CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LYMPHOMA; METABOLISM; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CANIS FAMILIARIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOMA; P-GLYCOPROTEIN; PHOSPHORYLCHOLINE; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 84902540272     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2014.04.002     Document Type: Article

References (27)

1. Bergman P.J. Mechanisms of anticancer drug resistance. Veterinary Clinics of North America. Small Animal Practice 2003, 33:651-667.
2. Bergman P.J., Ogilvie G.K., Powers B.E. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein. Sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996, 10:354-359.
3. Chang K.Y., Tsai S.Y., Wu C.M., Yen C.J., Chuang B.F., Chang J.Y. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clincal Cancer Research 2011, 17:7116-7126.
4. Chiarini F., Del Sole M., Mongiorgi S., Gaboardi G.C., Cappellini A., Mantovani I., Follo M.Y., McCubrey J.A., Martelli A.M. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008, 22:1106-1116.
5. Crul M., Rosing H., de Klerk G.J., Dubbelman R., Traiser M., Reichert S., Knebel N.G., Schellens J.H., Beijnen J.H., ten Bokkel Huinink W.W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. European Journal of Cancer 2002, 38:1615-1621.
6. Dobson J.M., Blackwood L.B., McInnes E.F., Bostock D.E., Nicholls P., Hoather T.M., Tom B.D. Prognostic variables in canine multicentric lymphosarcoma. Journal of Small Animal Practice 2001, 42:377-384.
7. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002, 16:704-709.
8. Gromicho M., Dinis J., Magalhaes M., Fernandes A.R., Tavares P., Laires A., Rueff J., Rodrigues A.S. Development of imatinib and dasatinib resistance. Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leukemia and Lymphoma 2011, 52:1980-1990.
9. Hiraoka H., Minami K., Kaneko N., Shimokawa Miyama T., Okamura Y., Mizuno T., Okuda M. Aberrations of the FHIT gene and Fhit protein in canine lymphoma cell lines. Journal of Veterinary Medical Science 2009, 71:769-777.
10. Keller E.T., MacEwen E.G., Rosenthal R.C., Helfand S.C., Fox L.E. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 1993, 7:289-295.
11. Lee J.J., Hughes C.S., Fine R.L., Page R.L. P-glycoprotein expression in canine lymphoma. A relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892-1898.
12. Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs. A review of recent developments and future prospects. The Veterinary Journal 2011, 188:34-38.
13. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Current Opinion in Pharmacology 2006, 6:350-354.
14. Moore A.S., Leveille C.R., Reimann K.A., Shu H., Arias I.M. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Investigation 1995, 13:475-479.
15. Moore A.S., Cotter S.M., Rand W.M., Wood C.A., Williams L.E., London C.A., Frimberger A.E., L'Heureux D.A. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Journal of Veterinary Internal Medicine 2001, 15:348-354.
16. Nakaichi M., Taura Y., Kanki M., Mamba K., Momoi Y., Tsujimoto H., Nakama S. Establishment and characterization of a new canine B-cell leukemia cell line. Journal of Veterinary Medical Science 1996, 58:469-471.
17. O'Connor R. The pharmacology of cancer resistance. Anticancer Research 2007, 27:1267-1272.
18. Rutgen B.C., Hammer S.E., Gerner W., Christian M., de Arespacochaga A.G., Willmann M., Kleiter M., Schwendenwein I., Saalmuller A. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leukemia Research 2010, 34:932-938.
19. Schmidt-Hieber M., Dabrowski R., Weimann A., Aicher B., Lohneis P., Busse A., Thiel E., Blau I.W. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines. Investigational New Drugs 2012, 30:480-489.
20. Skolnik J.M., Barrett J.S., Shi H., Adamson P.C. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemotherapy and Pharmacology 2006, 57:458-464.
21. Srivastava N., Cho D.C. Perifosine in renal cell carcinoma. Expert Opinion on Investigational Drugs 2013, 22:285-291.
22. Tomiyasu H., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. Journal of Veterinary Medical Science 2010, 72:1165-1172.
23. Tomiyasu H., Watanabe M., Goto-Koshino Y., Fujino Y., Ohno K., Sugano S., Tsujimoto H. Regulation of expression of ABCB1 and LRP genes by mitogen-activated protein kinase/extracellular signal-regulated kinase pathway and its role in generation of side population cells in canine lymphoma cell lines. Leukemia and Lymphoma 2013, 54:1309-1315.
24. Tomiyasu H., Goto-Koshino Y., Fujino Y., Ohno K., Tsujimoto H. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. The Veterinary Journal 2013, 199:103-109.
25. van Blitterswijk W.J., Verheij M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochimica et Biophysica Acta 2013, 1831:663-674.
26. Yamazaki J., Baba K., Goto-Koshino Y., Setoguchi-Mukai A., Fujino Y., Ohno K., Tsujimoto H. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Veterinary Immunology and Immunopathology 2008, 126:321-331.
27. Zhu M.M., Tong J.L., Xu Q., Nie F., Xu X.T., Xiao S.D., Ran Z.H. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS ONE 2012, 7:e41763.